Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Neil Doherty

Cardiovascular Disease Glendora, CA Medical Doctor

NPI 1871562017 CMS profile 85481

552 W Foothill Blvd Ste 201, Glendora, CA 91741

Open in the dashboard

General payments

$8,697

376 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Neil Doherty of Glendora, CA is reported in the CMS Open Payments database as having received $8,697 across 376 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $703 28
2024 General $874 29
2023 General $2,816 49
2022 General $1,104 76
2021 General $1,307 70
2020 General $711 37
2019 General $1,182 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neil Doherty
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Neil Doherty were reported at $703. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Neil Doherty Cardiovascular Disease median Middle half National median
2019 $1,182 $450 $127–$1,392 $163
2020 $711 $242 $77–$751 $114
2021 $1,307 $335 $101–$1,037 $132
2022 $1,104 $395 $121–$1,211 $149
2023 $2,816 $443 $136–$1,283 $160
2024 $874 $450 $136–$1,323 $164
2025 $703 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $2,210 15 payments
  2. Amarin Pharma Inc. $777 59 payments
  3. Novartis Pharmaceuticals Corporation $697 43 payments
  4. Amgen Inc. $641 35 payments
  5. E.R. Squibb & Sons, L.L.C. $636 64 payments
  6. Kowa Pharmaceuticals America, Inc. $504 24 payments
  7. Merck Sharp & Dohme Corporation $487 26 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $356 16 payments
  9. Edwards Lifesciences Corporation $279 8 payments
  10. Kiniksa Pharmaceuticals International, plc $268 6 payments
  11. Other $1,842 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,732 353 payments
  2. Travel and Lodging $1,761 6 payments
  3. Education $203 17 payments
Products named General payments · program years 2019–2025
  1. Micra $2,015 14 payments
  2. Vascepa $639 39 payments
  3. Repatha $592 33 payments
  4. VERQUVO $586 31 payments
  5. Livalo $466 22 payments
  6. ELIQUIS $464 54 payments
  7. Bystolic $356 17 payments
  8. ENTRESTO $340 24 payments
  9. JARDIANCE $333 15 payments
  10. Corlanor $244 15 payments
  11. Other $3,359 158 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,274

Median for Cardiology: 2,533

Drug cost

$396,905

Median for Cardiology: $485,213

Branded share of claims

21.2%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 197 $204,164
Multaq Dronedarone Hcl Brand 34 $39,112
Jardiance Empagliflozin Brand 26 $31,127
Entresto Sacubitril/Valsartan Brand 19 $27,173
Xarelto Rivaroxaban Brand 27 $26,007
Repatha Sureclick Evolocumab Brand 11 $15,313
Vascepa Icosapent Ethyl Brand 61 $11,943
Brilinta Ticagrelor Brand 11 $8,680
Zetia Ezetimibe Brand 15 $6,850
Ezetimibe Generic 184 $5,028

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$91,253

Of which drugs: $135

Medicare patients

399

Average age 76

Services billed

1,409

203 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 68%
Diabetes 46%
Arthritis 45%
Heart failure 29%
Atrial fibrillation 29%
Chronic kidney disease 26%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 13 52 $135

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $268
$268 — —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $118
$118 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $99
$99 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $98
$98 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

376 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record